Press Releases

Filter by year

March 25, 2024

Starton Therapeutics to Present at Upcoming MedInvest and Needham Conferences

February 23, 2024

Starton Therapeutics to Present at BIO CEO & Investor Conference 2024

February 14, 2024

Starton Therapeutics Announces Opening of Second Clinical Site for STAR-LLD Phase 1b Trial in Multiple Myeloma and Provides Study Update

January 17, 2024

Starton Therapeutics Announces STARTICLES Filing

January 3, 2024

Starton Therapeutics Announces Initial Key Safety and Efficacy Signals with STAR-LLD in Patients with Relapsed or Refractory Multiple Myeloma

January 2, 2024

Starton Therapeutics Announces the Launch of STARSILON a Novel Proprietary Transdermal PATCH Delivery Platform

December 18, 2023

Starton Therapeutics to Present at Biotech Showcase 2024 in San Francisco

November 20, 2023

Starton Therapeutics Completes One Third of STAR-LLD Study Enrollment

November 4, 2023

Starton Therapeutics Announces Termination of Business Combination Agreement with Healthwell Acquisition Corp. I

October 4, 2023

Starton Therapeutics Doses First Patient in Landmark STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma

September 13, 2023

Starton Therapeutics Announces the Opening of the First Clinical Site for STAR-LLD Lenalidomide Phase 1b Trial in Multiple Myeloma

July 10, 2023

Starton Therapeutics Contracts Global Clinical Research Organization to Conduct STAR-LLD Phase 1b Clinical Trial in Multiple Myeloma

June 12, 2023

Starton Therapeutics Receives Authorization from the FDA to Proceed with STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma

April 27, 2023

Starton Therapeutics Inc. and Healthwell Acquisition Corp. I to Combine and Create Publicly Traded Leader in Proprietary Continuous Delivery Technology for Cancer Treatments

December 12, 2022

Starton Therapeutics’ STAR-LLD Continuous Delivery Shows Superior Tumor Reduction and Progression Free Survival (PFS) Compared to Pulsatile Lenalidomide Treatment in Lenalidomide-Resistant Model

September 27, 2022

Starton Therapeutics Announces Appointment of Moses Dodo to Its Board of Directors

August 18, 2022

Starton Therapeutics to Present Poster at International Myeloma Society Annual Meeting 2022

July 13, 2022

Starton Therapeutics Reports Positive Results from Phase 1 Study Evaluating STAR-LLD, Continuous Delivery Lenalidomide

May 23, 2022

Starton Therapeutics Announces Approval to Proceed with Final Dose Escalation in Phase 1 Clinical Study Evaluating STAR-LLD

May 4, 2022

Starton Therapeutics Provides Update on STAR-LLD Lenalidomide Clinical Program

April 25, 2022

Starton Therapeutics Doses First Subjects in Phase 1 Clinical Trial of STAR-LLD Continuous Delivery Lenalidomide

April 4, 2022

Starton Therapeutics Announces FDA Clearance of IND Application for STAR-OLZ TDS for the Treatment of CINV

January 24, 2022

Starton Therapeutics Successfully Demonstrates Continuous Drug Delivery of Lenalidomide from a Transdermal Patch in an In Vivo Nonclinical Study with STAR-LLD

January 10, 2022

Starton Therapeutics Receives Clinical Trial Authorization in Europe to Initiate Phase 1 Clinical Trial of STAR-LLD Continuous Delivery Lenalidomide

October 4, 2021

Starton Therapeutics Announces Notice of Allowance for U.S. Patent Application Protecting Continuous Delivery of Lenalidomide and Other Immunomodulatory Agents

September 30, 2021

Starton Therapeutics Announces Successful Results in STAR-LLD Toxicology Study: No Myelosuppression and Excellent Tolerability

June 16, 2021

Starton Therapeutics Phase 2 TROPIC-I Clinical Study will be First to Use Total Control Primary Endpoint in Superiority Study

June 10, 2021

Starton Therapeutics to Present at 2021 BIO Digital

June 9, 2021

Starton Therapeutics Advances STAR-LLD Transdermal Lenalidomide Following Successful Skin Permeation Studies

April 7, 2021

Starton Therapeutics to Participate in the Virtual 20th Annual Needham Healthcare Conference

March 22, 2021

Starton Therapeutics Completes Pre-IND Meeting with FDA: Clearing Path to Phase 1 Clinical Study for STAR-LLD Continuous Infusion

March 1, 2021

Starton Therapeutics and Haisco Pharmaceutical Announce an Exclusive Licensing Agreement to Develop and Commercialize STAR-OLZ for Nausea and Vomiting in China

January 11, 2021

Starton Therapeutics Selects Formulation for Continuous Subcutaneous Lenalidomide Delivery System for CLL Treatment 

September 14, 2020

Keith Darragh Joins Starton Therapeutics as Chief Financial Officer

September 9, 2020

Drs. Kenneth Anderson and Asher Chanan-Khan to Join Starton Therapeutics Board of Directors 

August 25, 2020

Cidnee Vaykovich Named Starton Therapeutics Chief Operating Officer

July 28, 2020

Starton Therapeutics to Present at the LifeSci Partners Summer Symposium

April 30, 2020

Starton Therapeutics Files PCT and US Patent Application for Continuous Delivery of Lenalidomide and Class of Immunomodulatory Agents

December 27, 2019

Starton Successfully Completes Proof of Concept Study for Transdermal Lenalidomide

December 26, 2019

Starton Therapeutics: Announcing Name Change for ChemioCare Inc

December 18, 2019

ChemioCare Completes Successful Human Bioavailability Study for Novel 7-Day Olanzapine Transdermal Delivery System

August 29, 2019

ChemioCare Strengthens its Proposed Slate of Directors with the Nomination of Multiple Myeloma Expert Dr. Mohamad Hussein

April 29, 2019

ChemioCare Announces Appointment of Roy F. Waldron to Its Board of Directors

April 23, 2019

ChemioCare Announces Initiation of PETT Based (Permeation Enhanced Transdermal Technology) Lenalidomide Program

February 6, 2019

ChemioCare Reports Positive Animal Study Results for CMIO-Ondan Patch

January 7, 2019

ChemioCare Strengthens Executive Management Team

January 4, 2019

ChemioCare Initiates Development Program in Pediatric CINV

October 18, 2018

ChemioCare Expands Proprietary Transdermal Platform

July 30, 2018

ChemioCare Announces Addition of Three Experienced Team Members

May 1, 2018

ChemioCare Announces Addition of Chief Medical Advisor and Director

March 6, 2018

ChemioCare Formed to Transform Chemo-Induced Emesis Outcomes Through Patch Technology